



**HAL**  
open science

## **Fused Systems Based on 2-Aminopyrimidines: Synthesis Combining Deprotolithiation-in situ Zincation with N -Arylation Reactions and Biological Properties**

Madani Hedidi, Julien Maillard, William Erb, Frédéric Lassagne, Yury S Halauko, Oleg A Ivashkevich, Vadim E Matulis, Thierry Roisnel, Vincent Dorcet, Monzer Hamze, et al.

### ► To cite this version:

Madani Hedidi, Julien Maillard, William Erb, Frédéric Lassagne, Yury S Halauko, et al.. Fused Systems Based on 2-Aminopyrimidines: Synthesis Combining Deprotolithiation-in situ Zincation with N -Arylation Reactions and Biological Properties. *European Journal of Organic Chemistry*, 2017, 2017 (39), pp.5903-5915. <10.1002/ejoc.201701004>. <hal-01624382>

**HAL Id: hal-01624382**

**<https://univ-rennes.hal.science/hal-01624382v1>**

Submitted on 26 Oct 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

# Fused systems based on 2-aminopyrimidines: synthesis combining deprotolithiation-in situ zincation with *N*-arylation reactions and biological properties

Madani Hedidi,<sup>[a,b,c]</sup> Julien Maillard,<sup>[a]</sup> William Erb,<sup>[a]</sup> Frédéric Lassagne,<sup>[a]</sup> Yury S. Halauko,<sup>\*,[d]</sup> Oleg A. Ivashkevich,<sup>[d]</sup> Vadim E. Matulis,<sup>[e]</sup> Thierry Roisnel,<sup>[f]</sup> Vincent Dorcet,<sup>[f]</sup> Monzer Hamzé,<sup>[g]</sup> Ziad Fajloun,<sup>\*,[h]</sup> Blandine Baratte,<sup>[i]</sup> Sandrine Ruchaud,<sup>[i]</sup> Stéphane Bach,<sup>\*,[i]</sup> Ghena Bentabed-Ababsa<sup>\*,[b]</sup> and Florence Mongin<sup>\*,[a]</sup>

- [a] Dr. M. Hedidi, J. Maillard, Dr. W. Erb, F. Lassagne, Prof. F. Mongin  
Equipe Chimie Organique et Interfaces  
Institut des Sciences Chimiques de Rennes  
UMR 6226 CNRS - Université de Rennes 1  
Bâtiment 10A, Case 1003, Campus Scientifique de Beaulieu  
35042 Rennes, France  
E-mail: florence.mongin@univ-rennes1.fr  
<https://iscr.univ-rennes1.fr/corint/bimetallic-synergy>
- [b] Dr. M. Hedidi, Prof. G. Bentabed-Ababsa  
Laboratoire de Synthèse Organique Appliquée  
Faculté des Sciences Exactes et Appliquées  
Université d'Oran 1 Ahmed Ben Bella, BP 1524 El M'Naouer  
31000 Oran, Algeria  
E-mail: badri\_sofi@yahoo.fr
- [c] Dr. M. Hedidi  
Département chimie, Faculté des Sciences Exactes et Informatique  
Université Hassiba Benbouali de Chlef, Hay Es-salam RN 19  
02000 Chlef, Algeria (present address)
- [d] Dr. Y. S. Halauko, Prof. O. A. Ivashkevich  
UNESCO Chair of Belarusian State University  
14 Leningradskaya Str.  
Minsk 220030, Belarus  
E-mail: hys@tut.by
- [e] Dr. V. E. Matulis  
Research Institute for Physico-Chemical Problems  
of Belarusian State University  
14 Leningradskaya Str.  
Minsk 220030, Belarus
- [f] Dr. T. Roisnel, Dr. Vincent Dorcet  
Centre de Diffractométrie X  
Institut des Sciences Chimiques de Rennes  
UMR 6226 CNRS - Université de Rennes 1  
Bâtiment 10B, Campus de Beaulieu  
35042 Rennes, France
- [g] Dr. M. Hamzé  
Laboratoire Microbiologie, Santé et Environnement (LMSE), EDST,  
Faculté de Santé Publique, Lebanese University  
Tripoli, Lebanon
- [h] Dr. Z. Fajloun  
Laboratory of Applied Biotechnology  
Azm Center for Research in Biotechnology and its Applications  
EDST & Faculty of Science III, Lebanese University  
Tripoli, Lebanon  
E-mail: ziad.fajloun@ul.edu.lb
- [i] Dr. B. Baratte, Dr. S. Ruchaud, Dr. S. Bach  
Sorbonne Universités, UPMC Univ Paris 06, CNRS USR3151  
'Protein Phosphorylation and Human Disease' Unit  
Plateforme de criblage KISSf, Station Biologique de Roscoff  
Place Georges Teissier, 29688 Roscoff, France  
E-mail: bach@sb-roscoff.fr

Supporting information for this article is given via a link at the end of the document.

**Abstract:** Various aromatic ketones were first functionalized next to the carbonyl function by deprotolithiation in the presence of a zinc salt followed by iodolysis. The outcome of the reactions was

analyzed, and in particular their regioselectivity in the light of the calculated  $pK_a$  values. The various halogenated ketones were next involved in copper-catalyzed two-fold C-N bond formation in order to obtain fused systems based on 2-aminopyrimidines. Besides potential antibacterial effect, reached 2-aminobenzothiopyrano[4,3,2-*de*]quinazoline proved to inhibit PIM1 (IC<sub>50</sub>: 0.61  $\mu$ M) and CDK2/cyclin A (IC<sub>50</sub>: 2.0  $\mu$ M) kinases.

## Introduction

Aromatic ketones halogenated next to the carbonyl function are important key intermediates in organic synthesis. They can be used to access various scaffolds for applications in the fields of medicinal<sup>[1]</sup> and material<sup>[2]</sup> chemistry. Combining C-N bond formation<sup>[3]</sup> with condensation reactions<sup>[4]</sup> can provide an access from such ketones to elaborated fused systems based on 2-aminopyrimidines, potentially endowed with various biological properties.<sup>[5]</sup> However, in spite of their interest, few efficient methods presently exist to selectively introduce a halogen onto an aroyl group next to the carbonyl. Unlike electrophilic halogenation, that in general requires the presence of additional directing substituents,<sup>[1b,1c,2]</sup> transition-metal-catalyzed C-H bond halogenation using *N*-halo succinimides as oxidants can regioselectively provide aromatic ketones halogenated next to the carbonyl. Indeed, rhodium(III)-catalyzed bromination or iodination can be performed in the presence of catalytic silver hexafluoroantimonate(V), and stoichiometric pivalic acid or copper acetate,<sup>[6]</sup> whereas palladium-catalyzed chlorination can be achieved in the presence of triflic acid and potassium persulfate.<sup>[7]</sup> The former has not been applied to diaryl ketones<sup>[6]</sup> and the latter showed a coordination-driven regioselectivity.<sup>[7]</sup> We developed an alternative way based on polar-reagent-mediated deprotonative metalation in order to access various iodinated aromatic ketones.

We recently communicated our preliminary studies centered on the functionalization of pyridyl ketones by deprotolithiation-in situ zincation.<sup>[8]</sup> We here detail our investigations in order to better understand the behavior of the ketone function as directing group. Because CH acidity concept helps understand deprotometalation outcomes,  $pK_a$  values in THF (THF = tetrahydrofuran) solution were calculated by means of quantum chemistry within the DFT framework using an approach elaborated earlier.<sup>[8,9]</sup>

## Results and Discussion

Deprotolithiation has been largely used to activate aromatic compounds and make them react with a large range of electrophiles.<sup>[10]</sup> Whereas heteroatom-containing groups can help when connected to the aromatic ring, either by acidification (electron-withdrawing effect),<sup>[10e]</sup> or by metal coordination,<sup>[11]</sup> they can also modify the reaction outcome by reacting with the base or the generated aromatic lithium species as is the case for ketone functions.<sup>[12]</sup>

Because of their low compatibility with organolithiums, ketone-containing substrates have only been sporadically deprotometalated. Chromone and *N*-methyl quinolone could be deprotozincated using TMP-based zinc amides (TMP = 2,2,6,6-tetramethylpiperidino) either next to the carbonyl (3 position) or to the other heteroatom (2 position), respectively in the absence or presence of MgCl<sub>2</sub>, resulting of the Lewis acid coordination by the ketone.<sup>[13]</sup> Pyronones<sup>[13a,14]</sup> were functionalized at C3 by using TMPZnCl·LiCl whereas thiochromone<sup>[13a]</sup> was attacked at C2 by the same reagent. Tropolones were deprotometalated next to the function upon treatment by TMPZnCl·LiCl.<sup>[15]</sup> Five-membered heteroaromatic aldehydes<sup>[16]</sup> were similarly functionalized using TMP-based zinc amides. In contrast, very few diaryl ketones were concerned: benzoyl behaved as tolerated group in the TMPMgCl·LiCl-mediated deprotonation of a polysubstituted diethyl 1,3-phenylenedicarboxylate,<sup>[17]</sup> whereas it only acted as directing group in the deprotometalation of benzophenone using a lithium-cadmium base.<sup>[18]</sup>

Ketones are compatible to some extent with hindered lithium amides such as LiTMP, as shown for example in the generation of lithium enolates. In contrast, these functions are attacked by organolithiums.<sup>[19]</sup> Thus, to tackle the compatibility issue between organolithiums and ketones, we planned LiTMP-mediated deprotometalation in the presence of a zinc-based in situ trap. Studies have shown that it is possible to employ species such as Zn(TMP)<sub>2</sub><sup>[20]</sup> and ZnCl<sub>2</sub>·2LiCl<sup>[21]</sup> to intercept polar arylmetals. Within this study, we chose ZnCl<sub>2</sub>·TMEDA<sup>[22]</sup> (TMEDA = *N,N,N',N'*-tetramethylethylenediamine) as in situ trap to attempt deprotolithiation followed by 'trans-metal trapping'<sup>[23]</sup> and iodolysis from various diaryl ketones (Table 1).

Xanthone dimethyl acetal can be dimetalated next to the pyran oxygen (4 and 5 positions) in tetrahydropyran at -13 °C upon treatment by butyllithium (3 equiv.) in the presence of potassium *tert*-butoxide (3 equiv.), a result evidenced by subsequent trapping with iodomethane.<sup>[24]</sup> Treatment of xanthone (**1a**) in THF containing ZnCl<sub>2</sub>·TMEDA (1 equiv.) with LiTMP (1.5 equiv.) at -55 °C for 15 min and then iodine (1.5 equiv.) provided the 1-iodo derivative **2a** in 72% yield (entry 1). Thioxanthone (**1b**) was similarly converted to afford **2b** (entry 2). The calculated p*K*<sub>a</sub> values of **1a,b** can help rationalize this regioselectivity change and explain the directing group properties of the ketone. Compared with those next to the ketone function (1 and 8 positions), CH acidities next to the pyran or thiopyran heteroatom (4 and 5 positions) are higher. The observed deprotonation at the 1 position (beyond thermodynamic acidity)<sup>[11]</sup> could result from (i) ketone coordination to lithium, with induced acidity increase, (ii) favored

approach of the base, and/or (iii) stabilization. Indeed, when compared with esters and *N,N*-dialkylcarboxamides, the coordination ability of the ketone carbonyl group is known to be higher.<sup>[7]</sup>

**Table 1.** Substrates **1** and their calculated p*K*<sub>a</sub> (THF) values, and iodinated aromatic ketones **2** obtained by deprotometalation-iodination.

Entry	Ketone <b>1</b>	Iodoketone <b>2</b> , Yield <sup>[a]</sup> (%)
	1) ZnCl <sub>2</sub> ·TMEDA (1 equiv.) 2) LiTMP (1.5 equiv.) THF, -55 °C, 15 min 3) I <sub>2</sub> (1.5 equiv.) -55 °C to r.t.	
1	<b>1a</b>	<b>2a</b> , 72%
2	<b>1b</b>	<b>2b</b> , 53% 80% <sup>[b]</sup>
3	<b>1c</b>	<b>2c</b> , 52% <b>2c'</b> , 35%
4	<b>1d</b>	<b>2d</b> , 60% <b>2d'</b> , 10%
5	<b>1e</b>	<b>2e</b> , 60%
6	<b>1f</b>	<b>2f</b> , 33% <sup>[c]</sup> <b>2f'</b> , 20% <sup>[c]</sup>
7 <sup>[b]</sup>	<b>1g</b>	<b>2g</b> , 50% <sup>[d]</sup>

8 <sup>[b,e]</sup>		<b>1h</b>		<b>2h</b> , 45%
				<b>2h'</b> , 10%
9		<b>1i</b>		<b>2i</b> , 30% 37% <sup>[f]</sup>
10		<b>1j</b>		<b>2j</b> , 63%
11		<b>1k</b>		<b>2k</b> , 73%
12		<b>1l</b>		<b>2l</b> , 78%
13		<b>1m</b>		<b>2m</b> , 70%
14		<b>1n</b>		<b>2n</b> , 27%
15		<b>1o</b>		<b>2o</b> , 88%
16		<b>1p</b>		<b>2p</b> , 80%

[a] After purification by column chromatography. [b] Reaction carried out at -30 °C instead of -55 °C. [c] Other products also formed but could not be isolated or even identified. [d] A similar yield was obtained by using 2 equiv. of ZnCl<sub>2</sub>·TMEDA. [e] Reaction carried out by using 2 equiv. (instead of 1.5 equiv.) of LiTMP. [f] By performing the reaction at -70 °C (instead of -55 °C).

From xanthone (**1a**) to fluorenone (**1c**), changes were noticed. Thus, whereas the iodide **2a** was isolated in 72% yield (together with recovered starting material), the 1-iodo derivative **2c** was obtained in 52% yield due to the competitive formation of the keto-alcohol **2c'** (entry 3). The latter had previously been isolated in 63% yield by reacting fluorenone (**1c**) with the base prepared in situ from ZnCl<sub>2</sub>·TMEDA and LiTMP in a 1:3 ratio, and supposed to be LiTMP·Zn(TMP)<sub>2</sub>,<sup>[20]</sup> with Zn(TMP)<sub>2</sub> acting as in situ trap.<sup>[25]</sup> Because arylzincs hardly react with ketones,<sup>[26]</sup> **2c'** would rather result from an addition of the generated 1-lithiofluorenone onto starting **1c**. At first sight, this is surprising since fluorenone (**1c**) benefits from a more favorable CH acidity at its 1 position than xanthone (**1a**). That such a competitive

reaction does not take place from **1a** is in favor of an impact of the ketone carbonyl orientation on the stabilization of the lithio compound before its interception by 'trans-metal trapping'. This is also in accordance with data previously recorded with *N,N*-dialkylcarboxamides as deprotonation directing groups. Indeed, from studies performed on benzamides, Beak and co-workers suggest a correlation between the reaction efficiency and the distance from the directing group oxygen to the ortho hydrogen, as well as an optimal distance to accommodate the base effectively in the transition structure.<sup>[27]</sup>

By switching from symmetrical xanthone (**1a**) to the dissymmetrical azaxanthone **1d**, one moves from two different potential deprotonation sites to four. Nevertheless, from the two CH sites next to the carbonyl group, the pyridine 4 position is clearly the more acidified, and it is logically attacked to give the 4-iodo derivative **2d** in 60% yield (entry 4). The corresponding thio analog **2e** was obtained in 60% yield by reacting the azathioxanthone **1e** under the same conditions (entry 5). In the case of **1d**, the diiodide **2d'** resulting from a two-fold deprotonation at the 4 and 9 positions was also isolated (entry 4); that such a diiodo derivative is not formed from **1e** might result from a lower propensity of sulfur to coordinate lithium, when compared with oxygen.

Due to its strong ability to coordinate lithium, the pyridine nitrogen is a good candidate to compete with the ketone oxygen in coordinating metals. Thus, it is not surprising that the azafuorenone **1f** is also attacked at its 9 position (to afford **2f'** in 20% yield) in addition to the 4 one giving **2f** in 33% yield (entry 6). The second functionalization at the 9 position might happen after a first deprotonation-'trans-metal trapping' at the 4 position, as previously observed from other heterocycles.<sup>[9a,28]</sup>

Because of their π-deficiency, benzoylpyridines are more sensitive toward nucleophiles than simpler aryl ketones; not only the function, but also the pyridine ring (and in particular when the ketone function activates its 2 and 4 positions toward nucleophilic attack) can be subjected to the addition of organolithiums. From 2-benzoylpyridine (**1g**), optimization of the reaction conditions was carried out in THF containing ZnCl<sub>2</sub>·TMEDA (1 equiv.) by using four different reaction temperatures, between -70 and -10 °C, and four different amounts of LiTMP, between 1 and 3 equiv. The best results were observed when 1.5 equiv. of LiTMP were employed at -30 °C for 15 min before interception with iodine to furnish the 3-iodo derivative **2g** in 50% yield (entry 7). The reaction from 4-benzoylpyridine (**1h**) was performed as for its 2-isomer, but using 2 equiv. of LiTMP; under these conditions, the 3-iodo derivative **2h** was isolated in 45% yield (entry 8).


Among the three different benzoylpyridines used **1g-i**, 3-benzoylpyridine (**1i**) is by far the more sensitive due to its free 4 position next to the ketone function.<sup>[29]</sup> To limit side nucleophilic attacks, the reaction has to be conducted at lower temperatures. Under the conditions used to make **1a-f** react (reaction at -50 °C), the product **2i** resulting from a metalation at the 4 position was isolated from a complex mixture in 30% yield. At -70 °C, the result was slightly improved, with **2i** obtained in 37% yield (entry 9). Diiodides were suspected as side products in the course of the reactions coming from **1g-i**; unambiguously, such



Pyridopyrimidine is a core present in compounds of medicinal importance for their anticancer, CNS, fungicidal, antiviral, anti-inflammatory, antimicrobial and antibacterial properties.<sup>[36]</sup> To access such compounds, efficient synthetic methods are required. The two-fold functionalization of the bifunctional substrates **2** combining C-N bond formation<sup>[3]</sup> from the iodide with imine formation<sup>[4]</sup> from the ketone appears as an attracting way to reach original fused systems based on pyrido[2,3-*e*]pyrimidines.

To this end, we first considered the reaction between 2-benzoyl-3-iodopyridine (**2g**) and 3-amino-1,2,4-triazole (Table 2). Our attempt to obtain the 1,3,4,6,9b-pentaazacyclopenta[*a*]naphthalene **3g1** by simply heating the two coupling partners in the presence of a base (cesium carbonate) in DMF at 110 °C, as reported from 2-fluoro, 2-chloro and 2-bromo aryl ketones,<sup>[37]</sup> completely failed (entry 1). The starting materials were also recovered upon treatment by cesium carbonate and catalytic copper(I) oxide in DMSO at 110 °C (entry 2), which are suitable conditions for coupling iodopyridines.<sup>[38]</sup> Only traces of the expected product **3g1** were detected by using potassium carbonate and catalytic copper(I) iodide in either ethylene glycol (entry 3), or DMF containing ethylenediamine as ligand (entry 4), which are appropriate conditions for reacting 2-bromobenzaldehydes and 2-bromoaryl ketones with 3-aminopyrazoles.<sup>[4b]</sup> Finally, by keeping copper(I) iodide,<sup>[4b]</sup> employing potassium triphosphate as base,<sup>[39]</sup> and DMSO as solvent (no need of ligand),<sup>[38]</sup> led to **3g1**, which was isolated in 54% yield (entry 5; Figure 2, left).

**Table 2.** Optimization of the conversion of 2-benzoyl-3-iodopyridine (**2g**) into 5-phenyl-1,3,4,6,9b-pentaazacyclopenta[*a*]naphthalene (**3g1**).



Entry	Base	Catalyst	Ligand	Solvent	Yield <sup>[a]</sup>
1	Cs <sub>2</sub> CO <sub>3</sub>	-	-	DMF	-
2	Cs <sub>2</sub> CO <sub>3</sub>	Cu <sub>2</sub> O	-	DMSO	-
3	K <sub>2</sub> CO <sub>3</sub>	CuI	-	(CH <sub>2</sub> OH) <sub>2</sub>	traces
4	K <sub>2</sub> CO <sub>3</sub>	CuI	(CH <sub>2</sub> NH <sub>2</sub> ) <sub>2</sub>	DMF	traces
5	K <sub>3</sub> PO <sub>4</sub>	CuI	-	DMSO	54%


These conditions in hand, we attempted the reactions between 2-benzoyl-3-iodopyridine (**2g**) and other diamines (Table 3). Besides 3-amino-1,2,4-triazole (entry 1), we chose for this purpose commercial 3-aminopyrazole (entry 2), 2-aminobenzimidazole (entry 3) and guanidine (entry 4). Whereas the 4,6,7,11b-tetraazabenzoc[*c*]fluorene **3g3** was obtained in a

50% yield (entry 3; Figure 2, right) similar to **3g1** (entry 1), the 1,4,6,9b-tetraaza-cyclopenta[*a*]naphthalene **3g2** (entry 2) and 2-aminopyrido[3,2-*d*]pyrimidine **4g** (entry 4) were isolated in only 18% and 30% yield, respectively. For the latter, not only starting materials, but also deiodinated **1g**, were recovered.

**Table 3.** Conversion of the iodoketone **2g** into fused systems based on pyrido[2,3-*e*]pyrimidines.

Entry	Diamine	Product <b>3g</b> , Yield <sup>[a]</sup>
1		<b>3g1</b> , 54%
2		<b>3g2</b> , 18%
3		<b>3g3</b> , 50%
4		<b>4g</b> , 30%

[a] After purification by column chromatography.



**Figure 2.** ORTEP diagrams (30% probability) of compounds **3g1** and **3g3**.

The importance of that 2-aminopyrimidine motif in various biologically active scaffolds<sup>[5]</sup> prompted us to identify the reasons behind this failure. Optimization of the amounts employed in the reaction between 2-benzoyl-3-iodopyridine (**2g**) and guanidine was thus performed. It was noticed that increasing the amounts of both guanidine (to 2 equiv. of the hydrochloride) and base (to 4 equiv.) could lead to **4g** in an improved 77% yield (Table 4, entry 1, Figure 3). Albeit in a somewhat lower yield of 61%, the 2-aminopyrido[3,4-*d*]pyrimidine **4h** was similarly formed from 4-benzoyl-3-iodopyridine (**2h**) (entry 2).

In order to access the 2-aminopyrido[4,3-*d*]pyrimidines **4i** and **4o**, for which the pyridine nitrogen is at the 6 position, we respectively involved in the reaction the 3-benzoyl-4-iodopyridines (**2i** and **2o**). In spite of the known higher reactivity of 4-iodopyridines (higher partial positive charge on the carbon bearing the halogen) over 3-iodopyridines in copper-catalyzed C-N bond formation,<sup>[40]</sup> similar yields of 68% and 65% were remarked from **2i** and **2o** (entries 3 and 4, Figure 3).

To synthesize the isomer possessing the pyridine nitrogen at the 8 position, the 2-aminopyrido[2,3-*d*]pyrimidine **4j**, we rather reacted 3-benzoyl-2-fluoropyridine, easily prepared<sup>[41]</sup> from 2-fluoropyridine, with guanidine in the presence of potassium carbonate in dimethylacetamide at 135 °C<sup>[42]</sup> (entry 5, Figure 3).




Figure 3. ORTEP diagrams (30% probability) of compounds **4g**, **4i**, **4j** and **4d**.

In spite of the widespread biological properties of quinazolines, the derived tetracyclic benzopyrano<sup>[5b]</sup> and benzothiopyrano[4,3,2-*de*]quinazolines<sup>[43]</sup> (for which a 1,3-diazine ring is fused to a xanthene) have very rarely been synthesized. By applying the optimized method, we could

convert the iodides **2a** and **2b** into the corresponding 2-amino derivatives **4a** and **4b** in high yields (entries 6 and 7).

Table 4. Conversion of the iodoketones **2** into fused systems based on 2-aminopyrimidines.

Entry	Halogenoketone <b>2</b>	Product <b>4</b> , Yield <sup>[a]</sup>
1		<b>4g</b> , 77%
2		<b>4h</b> , 61%
3		<b>4i</b> , 68%
4		<b>4o</b> , 65%
5 <sup>[b]</sup>		<b>4j</b> , 94%
6		<b>4a</b> , 86%
7		<b>4b</b> , 84%
8		<b>4d</b> , 83%
9		<b>4e</b> , 88%

[a] After purification by column chromatography. [b] Reaction performed without CuI in the presence of K<sub>2</sub>CO<sub>3</sub> instead of K<sub>3</sub>PO<sub>4</sub>, and using dimethylacetamide as solvent at 135 °C.

The 7-oxa-1,3,6-triazabenz[de]anthracene skeleton has been reported once only<sup>[44]</sup> whereas the 7-thia analog has never been described. We could prepare for the first time 2-amino derivatives, the tetracycles **4d** and **4e** (entries 8 and 9, Figure 3), which are potential candidates for biological studies.

All the pyrimidine-containing products were evaluated for their biological properties. They were first screened for their antimicrobial activity against bacteria and for their antifungal activity (Table 5). An effect on the microbial growth of strains of bacteria was noticed in the case of **4g**, **4h**, **4i**, **4o**, **4j**, **4a**, **4b**, **4d** and **4e**, and a fairly broad spectrum of activity was precisely observed in the case of **4j** and **4b**, highlighting their potential antibacterial effect.

**Table 5.** Antimicrobial and antifungal activity of the compounds **3g1**, **3g2**, **3g3**, **4g**, **4h**, **4i**, **4o**, **4j**, **4a**, **4b**, **4d** and **4e**.<sup>[a]</sup>

Compound	Amount (µg dissolved in DMSO)	<i>Escherichia coli</i>	<i>Pseudomonas aeruginosa</i>	<i>Staphylococcus aureus</i>	<i>Enterococcus faecium</i>	<i>Listeria monocytogenes</i>	<i>Candida dubliniensis</i>
<b>3g1</b> <sup>[b]</sup>	250	±	±	0	±	0	0
<b>3g2</b> <sup>[b]</sup>	200	0	0	0	0	±	0
<b>3g3</b> <sup>[b]</sup>	200	0	0	0	0	0	0
<b>4g</b> <sup>[c]</sup>	250	-	-	±	13	24	19
<b>4h</b> <sup>[c]</sup>	250	-	-	-	8	27	-
<b>4i</b> <sup>[c]</sup>	250	-	-	±	12	20	17
<b>4o</b> <sup>[c]</sup>	250	10	±	±	13	32	23
<b>4j</b> <sup>[b]</sup>	250	10	17	±	8	-	13
<b>4a</b> <sup>[c]</sup>	250	-	-	±	10	16	±
<b>4b</b> <sup>[c]</sup>	250	15	17	±	13	17	17
<b>4d</b> <sup>[c]</sup>	250	-	-	±	10	-	-
<b>4e</b> <sup>[c]</sup>	250	-	-	±	12	-	-
DMSO	0	0	0	0	0	0	0
Reference compound	28	28	18	24	30	10	
	Ceftazidime (30 µg)	Vancomycin (30 µg)	Ampicillin (25 µg)	Nystatin (416 UI)			

[a] The diameters of zones of inhibition are given in mm. [b] 10 µL/well. [c] 50 µL/well.

As evidenced in Table 6, all the compounds showed an antioxidant activity around 50%. The hemolytic activity was tested for the compounds **4g**, **4h**, **4i**, **4o**, **4j**, **4a**, **4b**, **4d** and **4e** (250 µg) that showed an antimicrobial activity. Small hemolytic activities below 15% were recorded (data not shown). The absence or low toxicity on the human red blood cells, observed for products that have demonstrated an antimicrobial effect, highlights the value of their specific and selective antibacterial and antifungal effects and equally emphasizes a possible therapeutic interest of their application.

**Table 6.** Antioxidant activity of the compounds.

Compound	RSA (%) <sup>[a]</sup> at t = 0 min	RSA (%) <sup>[a]</sup> at t = 30 min
<b>4g</b>	42	46
<b>4h</b>	43	47
<b>4i</b>	43	49
<b>4o</b>	45	48
<b>4j</b>	48	51
<b>4a</b>	44	45
<b>4b</b>	44	49
<b>4d</b>	44	47
<b>4e</b>	45	46

[a] Percentage of the Radical Scavenger Activity.

Still in order to study the bioactivity of the synthesized compounds, we evaluated their bioactivity against a short panel of disease-related serine/threonine protein kinases: three human cyclin-dependent kinases (CDK2/Cyclin A, CDK5/p25 and CDK9/Cyclin T), human proto-oncogene PIM1, glycogen-synthase kinase-3 (native GSK-3 purified from porcine brain), receptor-interacting protein 3 (RIPK3), human mitotic kinases Haspin and Aurora B, and leishmania casein kinase 1 (*LmCK1* from *Leishmania major*).

Whereas none of the derivatives was shown to inhibit significantly CDK5/p25, CDK9/Cyclin T, GSK-3 and RIPK3, positive results were noticed with CDK2/Cyclin A, PIM1, *LmCK1*, Haspin and Aurora B (Table 7). These first results were then verified by testing the dose-dependent effect of the small chemical compounds against a selected panel of kinases (Table 8).

The inhibition reported for **4b** on PIM1 is interesting. Indeed, Horiuchi *et al.* showed that PIM1 kinase inhibition should be explored for developing targeted therapy against triple-negative breast tumors with elevated MYC expression.<sup>[45]</sup> Moreover, despite the structural similarities between the three CDKs tested, **4b** was shown to be selective for CDK2/Cyclin A.

**Table 7.** Inhibitory activities of synthesized compounds against a short panel of five disease-related protein kinases. The table displays the remaining activities detected after treatment with 10  $\mu\text{M}$  of the tested compounds. Results are expressed in % of maximal activity, i.e. measured in the absence of inhibitor. ATP concentration used in the kinase assays was 15  $\mu\text{mol/L}$  (values are means,  $n = 2$ ). Kinases are from human origin unless specified: *Lm*, *Leishmania major*.

Compound	CDK2/Cyclin A	PIM1	Haspin	Aurora B	<i>LmCK1</i>
<b>3g1</b>	78	82	103	109	56
<b>3g2</b>	57	87	117	49	61
<b>3g3</b>	82	81	102	70	65
<b>4g</b>	83	104	107	98	111
<b>4h</b>	67	92	99	60	65
<b>4i</b>	65	95	98	80	61
<b>4o</b>	76	74	115	106	47
<b>4j</b>	78	85	102	64	58
<b>4a</b>	70	49	65	51	<b>40</b>
<b>4b</b>	<b>41</b>	<b>32</b>	59	<b>40</b>	55
<b>4d</b>	54	86	73	<b>15</b>	<b>22</b>
<b>4e</b>	59	77	<b>41</b>	45	<b>37</b>

**Table 8.** Dose-dependent effect of the tested synthesized compounds on the kinase activities. The  $\text{IC}_{50}$  values are reported in  $\mu\text{M}$ . Compounds showing less than 50% inhibition at 10  $\mu\text{M}$  were considered as inactive (values are means,  $n = 3$ ).

Compound	CDK2/Cyclin A	PIM1	Haspin	Aurora B	<i>LmCK1</i>
<b>3g1</b>	>10	>10	>10	>10	>10
<b>3g2</b>	>10	>10	>10	>10	>10
<b>3g3</b>	>10	>10	>10	>10	>10
<b>4g</b>	>10	>10	>10	>10	>10
<b>4h</b>	>10	>10	>10	>10	>10
<b>4i</b>	>10	>10	>10	>10	>10
<b>4o</b>	>10	>10	>10	>10	<b>4.5</b>
<b>4j</b>	>10	>10	>10	>10	>10
<b>4a</b>	>10	>10	>10	>10	<b>6.5</b>
<b>4b</b>	<b>2.0</b>	<b>0.61</b>	>10	>10	>10
<b>4d</b>	>10	>10	>10	<b>1.9</b>	<b>1.8</b>
<b>4e</b>	>10	>10	>10	>10	<b>1.0</b>

## Conclusions

We showed that the carbonyl group of aromatic ketones can be efficiently employed to induce deprotonation at an adjacent site. The reaction can be carried out by using a hindered non-nucleophilic lithium amide in the presence of a zinc salt that acts as in situ trap. The usefulness of aromatic ketones halogenated

next to the carbonyl function was demonstrated by the synthesis of promising fused systems based on 2-aminopyrimidines.

## Experimental Section

All the reactions were performed under an argon atmosphere. THF was distilled over sodium/benzophenone. Column chromatography separations were achieved on silica gel (40-63  $\mu\text{m}$ ). Melting points were measured on a Kofler apparatus. IR spectra were taken on a Perkin-Elmer Spectrum 100 spectrometer.  $^1\text{H}$  and  $^{13}\text{C}$  Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker Avance III spectrometer at 300 MHz and 75 MHz, respectively.  $^1\text{H}$  chemical shifts ( $\delta$ ) are given in ppm relative to the solvent residual peak,  $^{13}\text{C}$  chemical shifts are relative to the central peak of the solvent signal,<sup>[46]</sup> and coupling constants ( $J$ ) are given in Hz.

1-Azaxanthone (**1d**),<sup>[47]</sup> 1-azathioxanthone (**1e**),<sup>[48]</sup> 1-azafluorenone (**1f**),<sup>[49]</sup> 3-benzoyl-2-fluoropyridine (**1j**),<sup>[41]</sup> 3-benzoyl-2-chloropyridine (**1k**),<sup>[41]</sup> 2-chloro-3-(2-chlorobenzoyl)pyridine (**1l**),<sup>[8]</sup> 2-chloro-3-(2-methoxybenzoyl)pyridine (**1m**),<sup>[8]</sup> 2-chloro-3-cinnamoylpyridine (**1n**),<sup>[8]</sup> 3-benzoyl-2-methoxyppyridine (**1o**),<sup>[41]</sup> and  $\text{ZnCl}_2$ -TMEDA<sup>[22]</sup> were prepared as described previously.

**General procedure 1 for the synthesis of the aryl iodides 2.** To a stirred mixture of the required ketone (1.0 mmol) and  $\text{ZnCl}_2$ -TMEDA (0.26 g, 1.0 mmol) in THF (3 mL) at  $-30\text{ }^\circ\text{C}$  was added dropwise a solution of LiTMP (prepared by adding BuLi (about 1.6 M hexanes solution, 1.5 mmol) to a stirred, cooled ( $0\text{ }^\circ\text{C}$ ) solution of 2,2,6,6-tetramethylpiperidine (0.25 mL, 1.5 mmol) in THF (3 mL) and stirring for 5 min) cooled at  $-30\text{ }^\circ\text{C}$ . After 15 min at  $-30\text{ }^\circ\text{C}$ , a solution of  $\text{I}_2$  (0.38 g, 1.5 mmol) in THF (5 mL) was introduced, and the mixture was stirred overnight before addition of an aqueous saturated solution of  $\text{Na}_2\text{S}_2\text{O}_3$  (5 mL) and extraction with AcOEt (3 x 20 mL). The combined organic layers were dried over  $\text{MgSO}_4$ , filtered and concentrated under reduced pressure. The crude product was purified by chromatography over silica gel (the eluent is given in the product description).

**General procedure 2 for the synthesis of the aryl iodides 2.** To a stirred mixture of the required ketone (1.0 mmol) and  $\text{ZnCl}_2$ -TMEDA (0.26 g, 1.0 mmol) in THF (3 mL) at  $-55\text{ }^\circ\text{C}$  was added dropwise a solution of LiTMP (prepared by adding BuLi (about 1.6 M hexanes solution, 1.5 mmol) to a stirred, cooled ( $0\text{ }^\circ\text{C}$ ) solution of 2,2,6,6-tetramethylpiperidine (0.25 mL, 1.5 mmol) in THF (3 mL) and stirring for 5 min) cooled at  $-55\text{ }^\circ\text{C}$ . After 15 min at  $-55\text{ }^\circ\text{C}$ , a solution of  $\text{I}_2$  (0.38 g, 1.5 mmol) in THF (5 mL) was introduced, and the mixture was stirred overnight before addition of an aqueous saturated solution of  $\text{Na}_2\text{S}_2\text{O}_3$  (5 mL) and extraction with AcOEt (3 x 20 mL). The combined organic layers were dried over  $\text{MgSO}_4$ , filtered and concentrated under reduced pressure. The crude product was purified by chromatography over silica gel (the eluent is given in the product description).

**General procedure 3 for the synthesis of the aryl iodides 2.** To a stirred mixture of the required ketone (1.0 mmol) and  $\text{ZnCl}_2$ -TMEDA (0.26 g, 1.0 mmol) in THF (3 mL) at  $-30\text{ }^\circ\text{C}$  was added dropwise a solution of LiTMP (prepared by adding BuLi (about 1.6 M hexanes solution, 2.0 mmol) to a stirred, cooled ( $0\text{ }^\circ\text{C}$ ) solution of 2,2,6,6-tetramethylpiperidine (0.33 mL, 2.0 mmol) in THF (3 mL) and stirring for 5 min) cooled at  $-30\text{ }^\circ\text{C}$ . After 15 min at  $-30\text{ }^\circ\text{C}$ , a solution of  $\text{I}_2$  (0.51 g, 2.0 mmol) in THF (5 mL), and the mixture was stirred overnight before addition of an aqueous saturated solution of  $\text{Na}_2\text{S}_2\text{O}_3$  (5 mL) and extraction with AcOEt (3 x 20 mL). The combined organic layers were dried over  $\text{MgSO}_4$ , filtered and concentrated under reduced pressure. The crude product was purified by

chromatography over silica gel (the eluent is given in the product description).

**General procedure 4 for the synthesis of the fused systems based on pyrido[2,3-*e*]pyrimidines 3g.** A mixture of CuI (20 mg, 0.10 mmol), the required amine (1.2 mmol), K<sub>3</sub>PO<sub>4</sub> (0.44 g, 2.0 mmol), 2-benzoyl-3-iodopyridine (**2g**, 0.31 g, 1.0 mmol) and DMSO (1.4 mL) was degassed and heated under argon and stirring at 110 °C for 16 h. After filtration over celite (washing using AcOEt) and removal of the solvents, the crude product is purified by chromatography over silica gel (the eluent is given in the product description).

**General procedure 5 for the synthesis of the fused systems based on 2-aminopyrimidines 4.** A mixture of CuI (20 mg, 0.10 mmol), guanidine hydrochloride (0.19 g, 2.0 mmol), K<sub>3</sub>PO<sub>4</sub> (0.88 g, 4.0 mmol), the required halogenopyridine (1.0 mmol) and DMSO (0.5 mL) was degassed and heated under argon at 110 °C for 24 h. After filtration over celite (washing using AcOEt) and removal of the solvents, the crude product is purified by chromatography over silica gel (the eluent is given in the product description).

**1-Iodo-9-xanthone (2a).** The general procedure 2 using 9-xanthone (**1a**, 0.20 g) gave **2a** (eluent: heptane-CH<sub>2</sub>Cl<sub>2</sub> 100:0 to 80:20) in 72% yield (0.23 g) as a pale yellow powder: mp 176 °C (lit.<sup>[24]</sup> 172-173.5 °C); IR (ATR): 663, 752, 777, 849, 903, 931, 1108, 1147, 1161, 1234, 1255, 1297, 1328, 1346, 1421, 1443, 1466, 1554, 1590, 1612, 1661, 3065 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.27 (dd, 1H, *J* = 8.4 and 7.8 Hz), 7.36 (ddd, 1H, *J* = 8.1, 7.2 and 0.9 Hz), 7.41 (dm, 1H, *J* = 9.0 Hz), 7.48 (dd, 1H, *J* = 8.4 and 1.2 Hz), 7.70 (ddd, 1H, *J* = 8.7, 7.2 and 1.8 Hz), 8.00 (dd, 1H, *J* = 7.6 and 1.1 Hz), 8.31 (ddd, 1H, *J* = 8.1, 1.8 and 0.5 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 91.3 (C), 117.7 (CH), 119.1 (CH), 120.1 (C), 121.3 (C), 124.3 (CH), 127.3 (CH), 134.7 (CH), 135.0 (CH), 138.6 (CH), 154.9 (C), 156.8 (C), 175.4 (C). These data are similar to those reported previously.<sup>[24]</sup>

**1-Iodo-9-thioxanthone (2b).**<sup>[25,50]</sup> The general procedure 2 using 9-thioxanthone (**1b**, 0.22 g) gave **2b** (eluent: heptane-CH<sub>2</sub>Cl<sub>2</sub> 100:0 to 80:20) in 53% yield (0.18 g) as a greenish powder: mp 156-158 °C; IR (ATR): 664, 711, 745, 777, 923, 1080, 1159, 1241, 1300, 1425, 1537, 1573, 1589, 1641, 3062 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.10 (t, 1H, *J* = 7.8 Hz), 7.41-7.47 (m, 2H), 7.52-7.60 (m, 2H), 8.14 (dd, 1H, *J* = 7.5 and 1.2 Hz), 8.47 (dm, 1H, *J* = 8.1 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 94.8 (C), 125.5 (CH), 126.7 (CH), 126.8 (CH), 127.7 (C), 129.6 (C), 130.2 (CH), 131.8 (CH), 132.3 (CH), 135.0 (C), 138.7 (C), 141.8 (CH), 179.5 (C).

**1-Iodo-9-fluorenone (2c).** The general procedure 2 using 9-fluorenone (**1c**, 0.18 g) gave **2c** (eluent: heptane-AcOEt 90:10) in 52% yield (0.16 g) as a yellow powder: mp 148 °C (lit.<sup>[51]</sup> 147-148.5 °C); IR (ATR): 733, 747, 784, 792, 918, 1056, 1085, 1126, 1149, 1186, 1257, 1281, 1295, 1437, 1563, 1588, 1606, 1715, 3048 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.15 (dd, 1H, *J* = 8.1 and 7.5 Hz), 7.33 (ddd, 1H, *J* = 10.2, 7.5 and 4.8 Hz), 7.49-7.56 (m, 3H), 7.68-7.74 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 91.6 (C), 120.1 (CH), 120.2 (CH), 124.7 (CH), 129.8 (CH), 134.0 (C), 134.1 (C), 135.0 (CH), 135.1 (CH), 140.6 (CH), 142.0 (C), 147.2 (C), 191.8 (C). **9'-Hydroxy-1,9'-bi-9-fluorenone (2c')** was also isolated in 35% yield (0.13 g) as a yellow powder: mp 222-224 °C (lit.<sup>[52]</sup> 222-224 °C); IR (ATR): 686, 728, 753, 771, 803, 909, 958, 1066, 1102, 1139, 1195, 1265, 1284, 1427, 1451, 1469, 1572, 1592, 1607, 1683, 2245, 3060, 3302 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.47 (dd, 1H, *J* = 8.1 and 0.9 Hz), 7.11 (dd, 1H, *J* = 8.1 and 7.5 Hz), 7.28 (td, 2H, *J* = 7.5 and 0.9 Hz), 7.33-7.42 (m, 4H), 7.47-7.57 (m, 4H), 7.70 (d, 2H, *J* = 7.2 Hz), 7.78 (d, 1H, *J* = 7.2 Hz), 7.94 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 85.5 (C), 119.9 (CH), 120.3 (2CH), 120.3 (CH), 124.7 (2CH), 125.3 (CH), 128.4 (CH), 128.4 (2CH), 129.2 (2CH), 129.6 (CH), 132.1 (C), 133.4 (C), 135.5 (CH), 136.0 (CH), 139.9 (2C), 144.3 (C), 146.8 (C), 148.8 (C), 149.5 (2C), 198.2 (C).

**4-Iodo-5H-benzopyrano[2,3-*b*]pyridin-5-one (2d).**<sup>[8]</sup> The general procedure 2 using 1-azaxanthone (**1d**, 0.20 g) gave **2d** (eluent: CH<sub>2</sub>Cl<sub>2</sub>-heptane 80:20) in 60% yield (0.19 g) as a yellow powder: mp 190-192 °C; IR (ATR): 728, 742, 761, 835, 922, 1085, 1115, 1183, 1219, 1248, 1274, 1318, 1346, 1367, 1443, 1464, 1537, 1557, 1612, 1659, 1724, 1978, 2925 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.40 (ddd, 1H, *J* = 8.1, 6.9 and 1.1 Hz), 7.52 (dq, 1H, *J* = 8.4 and 0.6 Hz), 7.74 (ddd, 1H, *J* = 8.7, 6.9 and 1.5 Hz), 8.01 (d, 1H, *J* = 5.1 Hz), 8.17 (d, 1H, *J* = 4.8 Hz), 8.26 (ddd, 1H, *J* = 8.1, 1.8 and 0.6 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 106.6 (C), 116.0 (C), 118.3 (CH), 121.0 (C), 125.1 (CH), 127.2 (CH), 135.6 (CH), 135.8 (CH), 152.3 (CH), 154.3 (C), 160.2 (C), 176.1 (C). **4,9-Diiodo-5H-benzopyrano[2,3-*b*]pyridin-5-one (2d')**<sup>[8]</sup> was also isolated in 10% yield (45 mg) as a yellow powder: mp 262-264 °C; IR (ATR): 734, 768, 920, 1019, 1101, 1266, 1369, 1428, 1444, 1538, 1655, 1722, 2924 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.20 (t, 1H, *J* = 7.8 Hz), 8.07 (d, 1H, *J* = 4.8 Hz), 8.21-8.25 (m, 2H), 8.29 (dd, 1H, *J* = 7.2 and 1.5 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 85.2 (C), 106.9 (C), 115.7 (C), 121.8 (C), 126.5 (CH), 127.7 (CH), 136.1 (CH), 145.6 (CH), 152.7 (CH), 153.5 (C), 160.2 (C), 175.9 (C).

**4-Iodo-5H-benzothiopyrano[2,3-*b*]pyridin-5-one (2e).**<sup>[8]</sup> The general procedure 2 using 1-azathioxanthone (**1e**, 0.21 g) gave **2e** (eluent: CH<sub>2</sub>Cl<sub>2</sub>) in 60% yield (0.20 g) as a yellow powder: mp 184-186 °C; IR (ATR): 697, 724, 802, 922, 1079, 1166, 1232, 1301, 1319, 1348, 1412, 1433, 1521, 1542, 1588, 1643, 1945, 2234, 2929, 3087 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.51 (ddd, 1H, *J* = 8.4, 6.9 and 1.2 Hz), 7.57 (ddd, 1H, *J* = 8.1, 1.5 and 0.6 Hz), 7.66 (ddd, 1H, *J* = 8.4, 6.9 and 1.5 Hz), 8.11 (d, 1H, *J* = 4.8 Hz), 8.17 (d, 1H, *J* = 5.1 Hz), 8.52 (ddd, 1H, *J* = 8.1, 1.5 and 0.6 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 107.4 (C), 125.3 (C), 125.9 (CH), 127.1 (CH), 128.9 (C), 130.4 (CH), 133.0 (CH), 135.2 (C), 136.8 (CH), 151.0 (CH), 159.7 (C), 179.8 (C).

**4-Iodo-5H-indeno[1,2-*b*]pyridin-5-one (2f).**<sup>[8]</sup> The general procedure 2 using 1-azafluorenone (**1f**, 0.18 g) gave **2f** (eluent: heptane-AcOEt 80:20) in 33% yield (0.10 g) as a yellow powder: mp 184 °C; IR (ATR): 669, 749, 805, 915, 1042, 1171, 1265, 1341, 1379, 1442, 1550, 1717 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.47 (td, 1H, *J* = 7.2 and 1.2 Hz), 7.61-7.67 (m, 2H), 7.76 (ddd, 1H, *J* = 7.2, 1.2 and 0.6 Hz), 7.87 (dt, 1H, *J* = 7.5 and 0.9 Hz), 8.14 (d, 1H, *J* = 5.4 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 102.4 (C), 121.3 (CH), 124.5 (CH), 129.4 (C), 131.7 (CH), 134.6 (CH), 135.0 (C), 135.7 (CH), 141.3 (C), 152.7 (CH), 166.2 (C), 190.1 (C). **4,9-Diiodo-5H-indeno[1,2-*b*]pyridin-5-one (2f')**<sup>[8]</sup> was also isolated in 20% yield (87 mg) as a yellowish powder: mp 244 °C; IR (ATR): 659, 693, 761, 783, 824, 924, 1054, 1102, 1164, 1266, 1338, 1369, 1454, 1543, 1556, 1713, 2854, 2924 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.13 (dd, 1H, *J* = 7.8 and 7.2 Hz), 7.70 (d, 1H, *J* = 5.4 Hz), 7.76 (dd, 1H, *J* = 7.5 and 1.1 Hz), 8.07 (dd, 1H, *J* = 7.8 and 2.0 Hz), 8.30 (d, 1H, *J* = 5.4 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 86.8 (C), 102.3 (C), 124.1 (CH), 129.6 (C), 132.2 (CH), 134.8 (CH), 137.1 (C), 141.4 (C), 147.5 (CH), 151.8 (CH), 165.8 (C), 188.7 (C).

**2-Benzoyl-3-iodopyridine (2g).**<sup>[8]</sup> The general procedure 1 using 2-benzoylpyridine (**1g**, 0.18 g) gave **2g** (eluent: heptane-AcOEt 80:20) in 50% yield (0.15 g) as a yellow powder: mp 98-100 °C; IR (ATR): 666, 702, 739, 795, 939, 1011, 1064, 1165, 1287, 1316, 1416, 1450, 1595, 1674, 3056 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.16 (dd, 1H, *J* = 8.1 and 4.8 Hz), 7.44-7.50 (m, 2H), 7.61 (tt, 1H, *J* = 7.4 and 1.4 Hz), 7.81-7.86 (m, 2H), 8.26 (dd, 1H, *J* = 8.1 and 1.2 Hz), 8.63 (dd, 1H, *J* = 4.5 and 1.5 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 89.8 (C), 125.6 (CH), 128.8 (2CH), 130.6 (2CH), 134.1 (CH), 134.8 (C), 147.3 (CH), 148.1 (CH), 159.2 (C), 194.3 (C).

**4-Benzoyl-3-iodopyridine (2h).**<sup>[8]</sup> The general procedure 3 using 4-benzoylpyridine (**1h**, 0.18 g) gave **2h** (eluent: heptane-AcOEt 80:20) in 45% yield (0.14 g) as a yellow powder: mp 92-94 °C; IR (ATR): 683, 701, 728, 835, 938, 1011, 1082, 1175, 1262, 1281, 1316, 1394, 1448, 1580, 1595, 1669, 3058 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.19 (dd, 1H, *J* = 4.8 and 0.6

Hz), 7.41-7.48 (m, 2H), 7.61 (tt, 1H,  $J = 7.4$  and  $1.4$  Hz), 7.72-7.76 (m, 2H), 8.61 (d, 1H,  $J = 4.8$  Hz), 8.97 (d, 1H,  $J = 0.9$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  91.0 (C), 122.3 (CH), 128.9 (2CH), 130.2 (2CH), 134.0 (C), 134.4 (CH), 148.6 (CH), 151.3 (C), 157.7 (CH), 194.7 (C). **4-Benzoyl-3,5-diiodopyridine (2h)**<sup>[8]</sup> was also isolated in 10% yield (43.5 mg) as a yellowish powder: mp 148 °C; IR (ATR): 683, 704, 728, 796, 934, 1037, 1174, 1202, 1270, 1314, 1389, 1450, 1499, 1580, 1595, 1672, 3059  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.52 (td, 2H,  $J = 7.7$  and  $0.9$  Hz), 7.68 (tt, 1H,  $J = 7.5$  and  $1.7$  Hz), 7.79-7.83 (m, 2H), 8.91 (s, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  90.7 (2C), 129.5 (2CH), 130.2 (2CH), 132.3 (C), 135.0 (CH), 155.4 (C), 156.3 (2CH), 194.8 (C).

**3-Benzoyl-4-iodopyridine (2i)**<sup>[8]</sup> The general procedure 2 using 3-benzoylpyridine (**1i**, 0.18 g), but performed at -70 °C instead of -55 °C, gave **2i** (eluent: heptane-AcOEt 80:20) in 37% yield (0.11 g) as a yellow powder: mp 136-138 °C; IR (ATR): 656, 705, 731, 918, 938, 1156, 1259, 1290, 1317, 1393, 1449, 1538, 1558, 1580, 1667, 2928, 3063  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.46-7.53 (m, 2H), 7.65 (tt, 1H,  $J = 7.4$  and  $2.7$  Hz), 7.78-7.84 (m, 2H), 7.91 (d, 1H,  $J = 5.4$  Hz), 8.31 (d, 1H,  $J = 5.4$  Hz), 8.45 (s, 1H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  104.4 (C), 129.0 (2CH), 130.5 (2CH), 134.4 (CH), 134.9 (CH), 135.4 (C), 140.5 (C), 148.2 (CH), 150.7 (CH), 195.1 (C).

**3-Benzoyl-2-fluoro-4-iodopyridine (2j)**<sup>[8]</sup> The general procedure 2 using 3-benzoyl-2-fluoropyridine (**1j**, 0.20 g) gave **2j** (eluent: heptane-AcOEt 80:20) in 63% yield (0.21 g) as a yellowish powder: mp 144 °C; IR (ATR): 660, 684, 827, 877, 926, 1171, 1230, 1271, 1316, 1391, 1442, 1449, 1539, 1574, 1669, 3084  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.46-7.53 (m, 2H), 7.65 (tt, 1H,  $J = 7.4$  and  $1.4$  Hz), 7.75 (dd, 1H,  $J = 5.4$  and  $1.1$  Hz), 7.79-7.83 (m, 2H), 7.97 (dd, 1H,  $J = 5.1$  and  $0.9$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  107.3 (d, C,  $J = 3.6$  Hz), 127.9 (d, C,  $J = 36$  Hz), 129.2 (2CH), 129.9 (2CH), 132.3 (d, CH,  $J = 4.5$  Hz), 134.8 (C), 134.8 (CH), 148.4 (d, CH,  $J = 15$  Hz), 158.8 (d, C,  $J = 241$  Hz), 191.6 (d, C,  $J = 3.5$  Hz).

**3-Benzoyl-2-chloro-4-iodopyridine (2k)**<sup>[53]</sup> The general procedure 2 using 3-benzoyl-2-chloropyridine (**1k**, 0.22 g) gave **2k** (eluent: heptane-AcOEt 80:20) in 73% yield (0.25 g) as a yellow powder: mp 130-132 °C; IR (ATR): 657, 684, 725, 799, 827, 923, 1162, 1195, 1217, 1266, 1313, 1360, 1428, 1449, 1528, 1547, 1581, 1595, 1668, 2927, 3062  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.47-7.54 (m, 2H), 7.65 (tt, 1H,  $J = 7.4$  and  $1.4$  Hz), 7.79-7.84 (m, 3H), 8.11 (d, 1H,  $J = 5.4$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  105.3 (C), 129.3 (2CH), 129.9 (2CH), 133.2 (CH), 134.0 (C), 134.8 (CH), 140.0 (C), 146.9 (C), 149.8 (CH), 193.1 (C).

**2-Chloro-3-(2-chlorobenzoyl)-4-iodopyridine (2l)**<sup>[8]</sup> The general procedure 2 using 2-chloro-3-(2-chlorobenzoyl)pyridine (**1l**, 0.25 g) gave **2l** (eluent: heptane-AcOEt 80:20) in 78% yield (0.29 g) as a yellowish powder: mp 112-114 °C; IR (ATR): 682, 732, 745, 761, 789, 829, 923, 1054, 1162, 1196, 1214, 1252, 1282, 1359, 1429, 1466, 1529, 1546, 1586, 1667, 1683, 3066  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.38 (ddd, 1H,  $J = 7.8$ , 6.6 and 1.8 Hz), 7.47-7.56 (m, 2H), 7.78 (d, 1H,  $J = 5.1$  Hz), 7.80 (ddd, 1H,  $J = 8.1$ , 1.8 and 0.6 Hz), 8.07 (d, 1H,  $J = 5.1$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  105.4 (C), 127.3 (CH), 132.0 (CH), 132.9 (CH), 133.2 (C), 133.5 (CH), 134.5 (CH), 134.7 (C), 140.8 (C), 146.9 (C), 149.7 (CH), 191.4 (C).

**2-Chloro-4-iodo-3-(2-methoxybenzoyl)pyridine (2m)**<sup>[8]</sup> The general procedure 2 using 2-chloro-3-(2-methoxybenzoyl)pyridine (**1m**, 0.25 g) gave **2m** (eluent: heptane-AcOEt 70:30) in 70% yield (0.26 g) as a yellow powder: mp 162-164 °C; IR (ATR): 693, 712, 747, 786, 835, 925, 1014, 1045, 1090, 1114, 1160, 1177, 1199, 1215, 1251, 1294, 1366, 1434, 1465, 1482, 1532, 1550, 1575, 1595, 1651, 1940, 2840, 2944  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  3.62 (s, 3H), 6.95 (dd, 1H,  $J = 8.4$  and  $0.9$  Hz), 7.11 (ddd, 1H,  $J = 8.1$ , 7.2 and  $0.9$  Hz), 7.60 (ddd, 1H,  $J = 9.0$ , 7.2 and  $0.9$  Hz), 7.74 (d, 1H,  $J = 5.1$  Hz), 8.01 (d, 1H,  $J = 5.4$  Hz), 8.06 (dd, 1H,  $J = 7.8$  and  $1.8$

Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  56.0 ( $\text{CH}_3$ ), 103.6 (C), 112.3 (CH), 121.3 (CH), 123.7 (C), 132.1 (CH), 132.8 (CH), 136.4 (CH), 143.5 (C), 145.9 (C), 148.3 (CH), 160.2 (C), 191.3 (C).

**2-Chloro-3-cinnamoyl-4-iodopyridine (2n)**<sup>[8]</sup> The general procedure 2 using 2-chloro-3-cinnamoylpyridine (**1n**, 0.24 g) gave **2n** (eluent: heptane-AcOEt 80:20) in 27% yield (0.10 g) as a yellow powder: mp 118-120 °C; IR (ATR): 680, 700, 733, 748, 765, 975, 1037, 1110, 1138, 1198, 1269, 1330, 1363, 1429, 1449, 1528, 1548, 1575, 1595, 1619, 1649, 2925, 3063  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.95 (d, 1H,  $J = 16$  Hz), 7.32 (d, 1H,  $J = 16$  Hz), 7.38-7.49 (m, 3H), 7.55-7.59 (m, 2H), 7.80 (d, 1H,  $J = 5.1$  Hz), 8.10 (d, 1H,  $J = 5.1$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  105.5 (C), 124.9 (CH), 129.0 (2CH), 129.3 (2CH), 131.7 (CH), 133.4 (CH), 134.0 (C), 140.2 (C), 146.9 (C), 148.5 (CH), 149.8 (CH), 193.2 (C).

**3-Benzoyl-4-iodo-2-methoxypyridine (2o)**<sup>[8]</sup> The general procedure 2 using 3-benzoyl-2-methoxypyridine (**1o**, 0.21 g) gave **2o** (eluent: heptane-AcOEt 80:20) in 88% yield (0.30 g) as a yellow powder: mp 144-146 °C; IR (ATR): 660, 685, 707, 730, 803, 847, 926, 1015, 1234, 1274, 1301, 1313, 1372, 1455, 1552, 1668, 2948  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  3.82 (s, 3H), 7.39 (d, 1H,  $J = 5.4$  Hz), 7.45 (tt, 2H,  $J = 7.5$  and  $1.7$  Hz), 7.59 (tt, 1H,  $J = 7.4$  and  $1.4$  Hz), 7.78-7.83 (m, 2H), 7.86 (d, 1H,  $J = 5.4$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  54.2 ( $\text{CH}_3$ ), 104.9 (C), 127.0 (CH), 128.6 (C), 128.9 (2CH), 129.7 (2CH), 134.1 (CH), 135.1 (C), 147.5 (CH), 160.5 (C), 194.5 (C).

**2-Benzoyl-5-iodothiophene (2p)**. The general procedure 2 using 2-benzoylthiophene (**1p**, 0.19 g) gave **2p** (eluent: heptane-AcOEt 80:20) in 80% yield (0.25 g) as a whitish powder: mp 129-131 °C (lit.<sup>[54]</sup> 132-133 °C); IR (ATR): 685, 696, 714, 783, 812, 857, 927, 952, 1066, 1138, 1213, 1297, 1316, 1378, 1405, 1443, 1516, 1575, 1595, 1613, 3054, 3228  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.27 (d, 1H,  $J = 3.9$  Hz), 7.33 (d, 1H,  $J = 3.9$  Hz), 7.46-7.53 (m, 2H), 7.57-7.63 (m, 1H), 7.80-7.85 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  86.0 (C), 128.6 (2CH), 129.1 (2CH), 132.6 (CH), 135.7 (CH), 137.6 (C), 138.1 (CH), 149.5 (C), 186.7 (C). These data are as described previously.<sup>[54]</sup>

**1-(2-Pyridyl)-9-xanthone (3a)**<sup>[8]</sup> To a stirred mixture of 9-xanthone (**1a**, 0.19 g, 1.0 mmol) and  $\text{ZnCl}_2$ -TMEDA (0.25 g, 1.0 mmol) in THF (3 mL) at -55 °C was added dropwise a solution of LiTMP (prepared by adding BuLi (about 1.6 M hexanes solution, 1.5 mmol) to a stirred, cooled (0 °C) solution of 2,2,6,6-tetramethylpiperidine (0.25 mL, 1.5 mmol) in THF (3 mL) and stirring for 5 min) cooled at -55 °C. After 15 min at -55 °C, 2-chloropyridine (0.55 g, 4.8 mmol), palladium(II) chloride (14 mg, 80  $\mu\text{mol}$ ) and 1,1'-diphenylphosphinoferrocene (44 mg, 80  $\mu\text{mol}$ ) were added to the reaction mixture, and the latter was heated at THF reflux for 16 h. After addition of water (0.5 mL) and EtOAc (50 mL), and drying over anhydrous  $\text{Na}_2\text{SO}_4$ , the solvent was evaporated under reduced pressure. The coupled product was isolated by purification by chromatography over silica gel (eluent: heptane-AcOEt 60:40 to 50:50) to afford **3a** in 76% yield (0.21 g) as a light grey powder: mp 183-184 °C; IR (ATR): 631, 672, 725, 750, 760, 786, 925, 1235, 1301, 1333, 1349, 1431, 1463, 1488, 1569, 1589, 1599, 1615, 1652, 2962, 3065  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.28-7.35 (m, 3H), 7.40 (d, 1H,  $J = 7.8$  Hz), 7.48 (d, 1H,  $J = 8.4$  Hz), 7.58 (dd, 1H,  $J = 8.4$  and  $0.7$  Hz), 7.69 (td, 1H,  $J = 7.8$  and  $1.5$  Hz), 7.74 (t, 1H,  $J = 7.9$  Hz), 7.77 (td, 1H,  $J = 7.7$  and  $1.7$  Hz), 8.16 (dd, 1H,  $J = 8.0$  and  $1.4$  Hz), 8.69 (d, 1H,  $J = 4.6$  Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  117.7 (CH), 118.7 (CH), 119.6 (C), 122.2 (CH), 122.7 (C), 123.7 (CH), 124.0 (CH), 126.5 (CH), 127.0 (CH), 133.9 (CH), 134.8 (CH), 135.6 (CH), 142.7 (C), 148.9 (CH), 155.6 (C), 157.1 (C), 159.9 (C), 176.9 (C).

**5-Phenyl-1,3,4,6,9b-pentaazacyclopenta[*a*]naphthalene (3g1)**. The general procedure 4 using 3-amino-1,2,4-triazole (0.10 g) gave **3g1** (eluent: heptane-AcOEt 50:50) in 54% yield (0.13 g) as a yellow powder:

mp 198 °C; IR (ATR): 681, 827, 1306, 1355, 1451, 1547, 1598, 3059 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.52-7.56 (m, 3H), 7.88 (dd, 1H, *J* = 8.6 and 4.4 Hz), 8.28-8.32 (m, 2H), 8.51 (m, 1H), 8.80 (dd, 1H, *J* = 8.6 and 1.7 Hz), 9.03 (dd, 1H, *J* = 4.4 and 1.7 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 123.8 (CH), 128.0 (CH), 128.2 (2CH), 131.1 (CH), 131.7 (2CH), 133.4 (C), 134.3 (C), 135.7 (C), 148.9 (CH), 152.3 (C), 155.4 (CH), 164.5 (C).

**5-Phenyl-1,4,6,9b-tetraaza-cyclopenta[a]naphthalene (3g2).** The general procedure 4 using 3-aminopyrazole (0.10 g) gave **3g2** (eluent: heptane-AcOEt 50:50) in 18% yield (44 mg) as a yellow powder: mp 180 °C; IR (ATR): 690, 742, 795, 811, 909, 1297, 1350, 1396, 1439, 1450, 1526, 1549, 1596, 3061 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.88 (d, 1H, *J* = 2.1 Hz), 7.53-7.59 (m, 3H), 7.79 (dd, 1H, *J* = 8.6 and 1.4 Hz), 8.14-8.18 (m, 3H), 8.86 (dd, 1H, *J* = 8.6 and 1.7 Hz), 8.92 (dd, 1H, *J* = 4.4 and 1.7 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 100.6 (CH), 123.3 (CH), 127.3 (CH), 128.3 (2CH), 130.2 (CH), 131.0 (2CH), 134.0 (C), 134.2 (C), 136.7 (C), 144.3 (CH), 145.1 (C), 147.6 (CH), 159.0 (C).

**5-Phenyl-4,6,7,11b-tetraazabenzoc[*c*]fluorene (3g3).** The general procedure 4 using 2-aminobenzimidazole (0.16 g) gave **3g3** (eluent: CH<sub>2</sub>Cl<sub>2</sub>-AcOEt 80:20) in 50% yield (0.15 g) as a yellow powder: mp 175 °C; IR (ATR): 684, 736, 1194, 1351, 1390, 1448, 1538, 1590 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.41-7.52 (m, 2H), 7.53-7.59 (m, 3H), 7.83 (dd, 1H, *J* = 8.7 and 1.5 Hz), 8.00 (dd, 1H, *J* = 8.1 and 1.5 Hz), 8.11 (dd, 1H, *J* = 8.4 and 1.2 Hz), 8.34-8.38 (m, 2H), 8.75 (dd, 1H, *J* = 8.6 and 1.4 Hz), 8.89 (dd, 1H, *J* = 4.2 and 1.2 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 113.2 (CH), 121.5 (CH), 122.6 (CH), 123.7 (CH), 125.2 (CH), 127.1 (CH), 128.1 (2CH), 129.4 (C), 130.9 (CH), 131.7 (2CH), 134.4 (C), 135.1 (C), 136.2 (C), 144.7 (C), 146.1 (CH), 149.0 (C), 164.1 (C).

**2-Amino-4-phenylpyrido[2,3-*d*]pyrimidine (4j).** The general procedure 5, but without Cul, using 3-benzoyl-2-fluoropyridine (**1j**, 0.20 g) gave **4j** (eluent: AcOEt-MeOH-NEt<sub>3</sub> 96:2:2) in 94% yield (0.21 g) as a yellowish powder: mp 192-194 °C; IR (ATR): 709, 730, 769, 786, 952, 1127, 1185, 1205, 1260, 1339, 1372, 1412, 1447, 1468, 1548, 1566, 1595, 1621, 2219, 3166, 3283, 3403 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.15 (br s, 2H), 7.13 (dd, 1H, *J* = 8.1 and 4.4 Hz), 7.52-7.56 (m, 3H), 7.64-7.68 (m, 2H), 8.13 (dd, 1H, *J* = 8.1 and 2.1 Hz), 8.94 (dd, 1H, *J* = 4.2 and 2.1 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 112.8 (C), 118.7 (CH), 128.8 (2CH), 129.6 (2CH), 130.4 (CH), 136.3 (C), 136.8 (CH), 157.5 (CH), 161.1 (C), 162.1 (C), 172.3 (C).

**2-Amino-4-phenylpyrido[3,2-*d*]pyrimidine (4g).**<sup>[6]</sup> The general procedure 5 using 2-benzoyl-3-iodopyridine (**2g**, 0.31 g) gave **4g** (eluent: heptane-AcOEt-NEt<sub>3</sub> 80:18:2) in 77% yield (0.17 g) as a yellowish powder: mp 140-142 °C; IR (ATR): 695, 739, 765, 804, 1124, 1231, 1344, 1376, 1422, 1458, 1548, 1583, 1601, 1628, 3060, 3171, 3313, 3477 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 5.67 (br s, 2H), 7.51-7.58 (m, 4H), 7.91 (dd, 1H, *J* = 8.7 and 1.7 Hz), 8.16-8.20 (m, 2H), 8.71 (dd, 1H, *J* = 3.9 and 1.7 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 127.9 (CH), 128.2 (2CH), 130.6 (CH), 131.2 (2CH), 133.8 (CH), 135.5 (C), 136.2 (C), 146.9 (CH), 149.5 (C), 159.9 (C), 169.4 (C).

**2-Amino-4-phenylpyrido[3,4-*d*]pyrimidine (4h).** The general procedure 5 using 4-benzoyl-3-iodopyridine (**2h**, 0.31 g) gave **4h** (eluent: heptane-AcOEt-NEt<sub>3</sub> 70:28:2) in 61% yield (0.14 g) as a yellow powder: mp 242-244 °C; IR (ATR): 673, 704, 764, 779, 808, 1026, 1155, 1227, 1378, 1415, 1488, 1545, 1567, 1584, 1660, 3082, 3301 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 5.46 (br s, 2H), 7.57-7.60 (m, 3H), 7.66 (dd, 1H, *J* = 5.7 and 1.1 Hz), 7.72-7.77 (m, 2H), 8.39 (d, 1H, *J* = 5.7 Hz), 9.14 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 118.7 (CH), 121.1 (C), 129.0 (2CH), 129.6 (2CH), 130.7 (CH), 136.1 (C), 141.3 (CH), 147.9 (C), 151.7 (CH), 160.5 (C), 170.6 (C).

**2-Amino-4-phenylpyrido[4,3-*d*]pyrimidine (4i).** The general procedure 5 using 3-benzoyl-4-iodopyridine (**2i**, 0.31 g) gave **4i** (eluent: heptane-

AcOEt-NEt<sub>3</sub> 70:28:2) in 68% yield (0.15 g) as a yellowish powder: mp 112-114 °C; IR (ATR): 703, 765, 834, 952, 1030, 1042, 1179, 1272, 1356, 1384, 1413, 1442, 1456, 1507, 1548, 1602, 1637, 3167, 3309 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.03 (br s, 2H), 7.38 (dd, 1H, *J* = 6.0 and 0.9 Hz), 7.53-7.60 (m, 3H), 7.71-7.75 (m, 2H), 8.60 (d, 1H, *J* = 6.0 Hz), 9.12 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 115.2 (C), 119.0 (CH), 128.9 (2CH), 129.8 (2CH), 130.8 (CH), 135.7 (C), 150.8 (CH), 152.3 (CH), 156.7 (C), 161.7 (C), 172.1 (C).

**2-Amino-5-methoxy-4-phenylpyrido[4,3-*d*]pyrimidine (4o).** The general procedure 5 using 3-benzoyl-4-iodo-2-methoxypyridine (**2o**, 0.34 g) gave **4o** (eluent: heptane-AcOEt-NEt<sub>3</sub> 80:18:2) in 65% yield (0.16 g) as a white powder: mp 146-148 °C; IR (ATR): 702, 837, 913, 980, 1104, 1131, 1290, 1321, 1367, 1435, 1447, 1540, 1559, 1600, 1634, 2949, 3176, 3312 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.69 (s, 3H), 5.89 (br s, 2H), 6.98 (d, 1H, *J* = 6.0 Hz), 7.40-7.50 (m, 5H), 8.13 (d, 1H, *J* = 6.0 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 53.4 (CH<sub>3</sub>), 105.6 (C), 113.9 (CH), 127.6 (2CH), 128.3 (2CH), 129.1 (CH), 140.4 (C), 148.4 (CH), 160.3 (C), 161.3 (C), 161.7 (C), 171.1 (C).

**2-Aminobenzopyrano[4,3,2-*de*]quinazoline (4a).** The general procedure 5 using 1-iodoxanthone (**2a**, 0.32 g) gave **4a** (eluent: AcOEt-heptane-NEt<sub>3</sub> 70:28:2) in 86% yield (0.20 g) as a yellow powder: mp 236-238 °C; IR (ATR): 717, 758, 816, 1053, 1072, 1249, 1259, 1324, 1348, 1435, 1453, 1490, 1561, 1596, 1615, 1640, 1667, 2854, 2924, 3173, 3302, 3481 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 5.21 (br s, 2H), 6.93 (dd, 1H, *J* = 8.1 and 0.8 Hz), 7.18 (dd, 1H, *J* = 8.4 and 0.8 Hz), 7.28-7.35 (m, 2H), 7.60 (ddd, 1H, *J* = 8.7, 7.2 and 1.8 Hz), 7.69 (dd, 1H, *J* = 8.4 and 8.1 Hz), 8.41 (ddd, 1H, *J* = 7.8, 1.8 and 0.6 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 105.9 (CH), 109.3 (C), 116.6 (CH), 117.7 (CH), 119.2 (C), 124.1 (CH), 125.0 (CH), 134.0 (CH), 135.4 (CH), 152.1 (C), 152.2 (C), 155.5 (C), 157.9 (C), 161.6 (C).

**2-Aminobenzothiopyrano[4,3,2-*de*]quinazoline (4b).** The general procedure 5 using 1-iodothioxanthone (**2b**, 0.34 g) gave **4b** (eluent: AcOEt-heptane-NEt<sub>3</sub> 70:28:2) in 84% yield (0.21 g) as a yellow powder: mp 258-260 °C; IR (ATR): 714, 758, 772, 815, 986, 1081, 1205, 1237, 1268, 1336, 1417, 1437, 1466, 1476, 1549, 1561, 1602, 1639, 1666, 1733, 2853, 2923, 3167, 3324 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 5.13 (br s, 2H), 7.12 (dd, 1H, *J* = 7.5 and 0.9 Hz), 7.27 (dd, 1H, *J* = 8.6 and 0.9 Hz), 7.33-7.40 (m, 2H), 7.47 (td, 1H, *J* = 6.6 and 1.5 Hz), 7.55 (dd, 1H, *J* = 8.4 and 7.5 Hz), 8.80 (dd, 1H, *J* = 8.7 and 1.5 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 115.2 (C), 116.8 (CH), 120.7 (CH), 125.9 (CH), 126.5 (CH), 127.7 (C), 128.2 (CH), 131.8 (CH), 133.2 (C), 133.4 (CH), 136.0 (C), 154.4 (C), 160.2 (C), 160.7 (C).

**2-Amino-7-oxa-1,3,6-triazabenz[*de*]anthracene (4d).** The general procedure 5 using 4-iodo-1-azaxanthone (**2d**, 0.32 g) gave **4d** (eluent: AcOEt-heptane-NEt<sub>3</sub> 80:18:2) in 83% yield (0.20 g) as a yellowish powder: mp > 264 °C; IR (ATR): 750, 837, 939, 1077, 1127, 1202, 1242, 1291, 1319, 1378, 1418, 1447, 1470, 1515, 1557, 1583, 1626, 1670, 3083, 3284 cm<sup>-1</sup>; <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>SO) δ 6.96 (d, 1H, *J* = 6.3 Hz), 7.45-7.51 (m, 3H), 7.60 (dd, 1H, *J* = 8.4 and 1.2 Hz), 7.79 (ddd, 1H, *J* = 8.7, 7.2 and 1.7 Hz), 6.24 (d, 1H, *J* = 6.0 Hz), 8.32 (dd, 1H, *J* = 8.0 and 1.7 Hz); <sup>13</sup>C NMR ((CD<sub>3</sub>)<sub>2</sub>SO) δ 102.8 (C), 112.9 (CH), 118.2 (CH), 118.3 (C), 124.1 (CH), 124.9 (CH), 134.6 (CH), 150.2 (CH), 154.5 (C), 158.1 (C), 158.2 (C), 158.3 (C), 164.1 (C).

**2-Amino-7-thia-1,3,6-triazabenz[*de*]anthracene (4e).** The general procedure 5 using 4-iodo-1-azathioxanthone (**2e**, 0.34 g) gave **4e** (eluent: AcOEt-heptane-NEt<sub>3</sub> 70:28:2) in 88% yield (0.22 g) as a yellow powder: mp 264-266 °C; IR (ATR): 725, 763, 809, 834, 1009, 1038, 1081, 1156, 1181, 1235, 1260, 1314, 1373, 1451, 1538, 1595, 1662, 2851, 2922, 2959, 3111, 3293 cm<sup>-1</sup>; <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>SO) δ 7.00 (d, 1H, *J* = 6.0 Hz), 7.43 (br s, 2H), 7.56 (ddd, 1H, *J* = 8.1, 5.7 and 3.0 Hz), 7.68-7.71 (m, 2H), 8.31 (d, 1H, *J* = 6.0 Hz), 8.75 (dt, 1H, *J* = 8.1 and 1.1 Hz); <sup>13</sup>C NMR

((CD<sub>3</sub>)<sub>2</sub>SO)  $\delta$  111.2 (C), 114.6 (CH), 126.1 (C), 126.6 (CH), 127.0 (CH), 127.3 (CH), 132.5 (CH), 135.5 (C), 150.0 (CH), 157.3 (C), 157.5 (C), 160.3 (C), 162.9 (C).

## Acknowledgements


We thank the Ministère de l'Enseignement supérieur et de la Recherche scientifique Algérien (M.H.), the Centre National de la Recherche Scientifique (CNRS), the Institut Universitaire de France and Rennes Métropole (F.M.). We also thank the Cancéropôle Grand-Ouest (axis: Marine natural products in cancer treatment), GIS IBISA (Infrastructures en Biologie Santé et Agronomie, France) and Biogenouest (Western France life science and environment core facility network) for supporting KISSf screening facility (Roscoff, France). We acknowledge FEDER funds (D8 VENTURE Bruker AXS diffractometer) and Thermofisher (generous gift of 2,2,6,6-tetramethylpiperidine). This research has been partly performed as part of the CNRS projet international de cooperation scientifique (PICS) project "Bimetallic synergy for the functionalization of heteroaromatics".

**Keywords:** ketones; pyrimidines; copper; C-N bond formation; C-H acidity

- [1] a) R. Romagnoli, P. G. Baraldi, M. D. Carrion, C. L. Cara, O. Cruz-Lopez, M. Tolomeo, S. Grimaudo, A. Di Cristina, M. R. Pipitone, J. Balzarini, N. Zonta, A. Brancale, E. Hamel, *Bioorg. Med. Chem.* **2009**, *17*, 6862–6871; b) W. Zhao, X. Feng, S. Ban, W. Lin, Q. Li, *Bioorg. Med. Chem. Lett.* **2010**, *20*, 4132–4134; c) D. Shi, J. Li, B. Jiang, S. Guo, H. Su, T. Wang, *Bioorg. Med. Chem. Lett.* **2012**, *22*, 2827–2832.
- [2] P. Rajamalli, N. Senthilkumar, P. Gandeepan, P.-Y. Huang, M.-J. Huang, C.-Z. Ren-Wu, C.-Y. Yang, M.-J. Chiu, L.-K. Chu, H.-W. Lin, C.-H. Cheng, *J. Am. Chem. Soc.* **2016**, *138*, 628–634.
- [3] a) F. Monnier, M. Taillefer, *Angew. Chem. Int. Ed.* **2009**, *48*, 6954–6971; b) I. P. Beletskaya, A. V. Cheprakov, *Organometallics* **2012**, *31*, 7753–7808; c) P. Ruiz-Castillo, S. L. Buchwald, *Chem. Rev.* **2016**, *116*, 12564–12649.
- [4] a) E. Dubost, S. Stiebing, T. Ferrary, T. Cailly, F. Fabis, V. Collot, *Tetrahedron* **2014**, *70*, 8413–8418; b) L. Gao, Y. Song, X. Zhang, S. Guo, X. Fan, *Tetrahedron Lett.* **2014**, *55*, 4997–5002; c) D. S. Baranov, D. S. Fadeev, *Mendeleev Commun.* **2016**, *26*, 174–176.
- [5] a) A. Kedrov, C. Ziegler, D. J. Muller, *J. Mol. Biol.* **2006**, *362*, 925–932; b) C. M. Martínez-Vituro, D. Domínguez, *J. Heterocycl. Chem.* **2007**, *44*, 1035–1043; c) L. Wei, S. V. Malhotra, *MedChemComm* **2012**, *3*, 1250–1257; d) M. Andaloussi, H. D. Lim, T. van der Meer, M. Sijm, C. B. M. Poullie, I. J. P. de Esch, R. Leurs, R. A. Smits, *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2663–2670; e) S. Lin, F. Han, P. Liu, J. Tao, X. Zhong, X. Liu, C. Yi, H. Xu, *Bioorg. Med. Chem. Lett.* **2014**, *24*, 790–793.
- [6] N. Schröder, J. Wencel-Delord, F. Glorius, *J. Am. Chem. Soc.* **2012**, *134*, 8298–8301.
- [7] X. Sun, G. Shan, Y. Sun, Y. Rao, *Angew. Chem., Int. Ed.* **2013**, *52*, 4440–4444.
- [8] M. Hedidi, W. Erb, F. Lassagne, Y. S. Halauko, O. A. Ivashkevich, V. E. Matulis, T. Roisnel, G. Bentabed-Ababsa, F. Mongin, *RSC Adv.* **2016**, *6*, 63185–63189.
- [9] a) R. R. Kadiyala, D. Tilly, E. Nagaradja, T. Roisnel, V. E. Matulis, O. A. Ivashkevich, Y. S. Halauko, F. Chevallier, P. C. Gros, F. Mongin, *Chem. Eur. J.* **2013**, *19*, 7944–7960; b) All the calculations were performed using the B3LYP hybrid functional. The single point energies were obtained using the 6-311+G(d,p) basis set after geometry optimization and calculation of the vibrational frequencies by using the 6-31G(d) basis set. The solvent influence was treated through the polarized continuum model (PCM) with the default parameters for THF, and the  $pK_a$  values were obtained from the Gibbs energy of the homodesmic reaction between the studied and probe aromatic substrates.
- [10] a) H. W. Gschwend, H. R. Rodriguez, *Org. React.* **1979**, *26*, 1–360; b) P. Beak, V. Snieckus, *Acc. Chem. Res.* **1982**, *15*, 306–312; c) V. Snieckus, *Chem. Rev.* **1990**, *90*, 879–933; d) T. G. Gant, A. I. Meyers, *Tetrahedron* **1994**, *50*, 2297–2360; e) M. Schlosser, *Organometallics in Synthesis* **2002**, 2nd ed. (Ed.: M. Schlosser), Wiley: New York, Chapter 1.
- [11] M. C. Whisler, S. MacNeil, V. Snieckus, P. Beak, *Angew. Chem. Int. Ed.* **2004**, *43*, 2206–2225.
- [12] P. Beak, G. R. Brubaker, R. F. Farney, *J. Am. Chem. Soc.* **1976**, *98*, 3621–3627.
- [13] a) L. Klier, T. Bresser, T. A. Nigst, K. Karaghiosoff, P. Knochel, *J. Am. Chem. Soc.* **2012**, *134*, 13584–13587; b) L. Klier, D. S. Ziegler, R. Rahimoff, M. Mosrin, P. Knochel, *Org. Process Res. Dev.* **2017**, *21*, 660–663.
- [14] M. Ehrlich, T. Carell, *Eur. J. Org. Chem.* **2013**, *2013*, 77–83.
- [15] D. Haas, D. Sustac-Roman, S. Schwarz, P. Knochel, *Org. Lett.* **2016**, *18*, 6380–6383.
- [16] a) S. H. Wunderlich, P. Knochel, *Angew. Chem. Int. Ed.* **2007**, *46*, 7685–7688; b) M. Mosrin, P. Knochel, *Org. Lett.* **2009**, *11*, 1837–1840; c) T. Bresser, M. Mosrin, G. Monzon, P. Knochel, *J. Org. Chem.* **2010**, *75*, 4686–4695.
- [17] W. Lin, O. Baron, P. Knochel, *Org. Lett.* **2006**, *8*, 5673–5676.
- [18] K. Snégaroff, J.-M. L'Helgoual'ch, G. Bentabed-Ababsa, T. T. Nguyen, F. Chevallier, M. Yonehara, M. Uchiyama, A. Derdour, F. Mongin, *Chem. Eur. J.* **2009**, *15*, 10280–10290.
- [19] Z. Zeng, S. C. Zimmerman, *Tetrahedron Lett.* **1988**, *29*, 5123–5124.
- [20] a) J. M. L'Helgoual'ch, A. Seggio, F. Chevallier, M. Yonehara, E. Jeanneau, M. Uchiyama, F. Mongin, *J. Org. Chem.* **2008**, *73*, 177–183; b) P. García-Álvarez, R. E. Mulvey, J. A. Parkinson, *Angew. Chem. Int. Ed.* **2011**, *50*, 9668–9671.
- [21] a) A. Frischmuth, M. Fernández, N. M. Barl, F. Achraimer, H. Zipse, G. Berionni, H. Mayr, K. Karaghiosoff, P. Knochel, *Angew. Chem. Int. Ed.* **2014**, *53*, 7928–7932; b) M. R. Becker, P. Knochel, *Angew. Chem. Int. Ed.* **2015**, *54*, 12501–12505; c) M. R. Becker, M. A. Ganiek, P. Knochel *Chem. Sci.* **2015**, *6*, 6649–6653.
- [22] R. A. Kjonaas, R. K. Hoffer, *J. Org. Chem.* **1988**, *53*, 4133–4135.
- [23] a) M. A. Fuentes, A. R. Kennedy, R. E. Mulvey, J. A. Parkinson, T. Rantanen, S. D. Robertson, V. Snieckus, *Chem. Eur. J.* **2015**, *21*, 14812–14822; b) M. Uzelac, A. R. Kennedy, E. Hevia, R. E. Mulvey, *Angew. Chem. Int. Ed.* **2016**, *55*, 13147–13150; c) R. McLellan, M. Uzelac, A. R. Kennedy, E. Hevia, R. E. Mulvey, *Angew. Chem. Int. Ed.* **2017**, *56*, 9566–9570.
- [24] M. R. Odrowaz-Sypniewski, P. G. Tsoungas, G. Varvounis, P. Cordopatis, *Tetrahedron Lett.* **2009**, *50*, 5981–5983.
- [25] R. Amara, G. Bentabed-Ababsa, M. Hedidi, J. Khoury, H. Awad, E. Nassar, T. Roisnel, V. Dorcet, F. Chevallier, Z. Fajloun, F. Mongin, *Synthesis* **2017**, *49*, accepted.
- [26] K. Snégaroff, S. Komagawa, F. Chevallier, P. C. Gros, S. Golhen, T. Roisnel, M. Uchiyama, F. Mongin, *Chem. Eur. J.* **2010**, *16*, 8191–8201.
- [27] P. Beak, S. T. Kerrick, D. J. Gallagher, *J. Am. Chem. Soc.* **1993**, *115*, 10628–10636.
- [28] a) F. Chevallier, Y. S. Halauko, C. Pecceu, I. F. Nassar, T. U. Dam, T. Roisnel, V. E. Matulis, O. A. Ivashkevich, F. Mongin, *Org. Biomol. Chem.* **2011**, *9*, 4671–4684; b) F. Chevallier, T. Blin, E. Nagaradja, F. Lassagne, T. Roisnel, Y. S. Halauko, V. E. Matulis, O. A. Ivashkevich, F. Mongin, *Org. Biomol. Chem.* **2012**, *10*, 4878–4885; c) E. Nagaradja, F. Chevallier, T. Roisnel, V. Dorcet, Y. S. Halauko, O. A. Ivashkevich, V. E. Matulis, F. Mongin, *Org. Biomol. Chem.* **2014**, *1475*–1487; d) E. Nagaradja, G. Bentabed-Ababsa, M. Scalabrini, F. Chevallier, S. Philippot, S. Fontanay, R. E. Duval, Y. S. Halauko, O. A. Ivashkevich, V.

- E. Matulis, T. Roisnel, F. Mongin, *Bioorg. Med. Chem.* **2015**, *23*, 6355–6363; e) M. Hedidi, G. Bentabed-Ababsa, A. Derdour, Y. S. Halauko, O. A. Ivashkevich, V. E. Matulis, F. Chevallier, T. Roisnel, V. Dorcet, F. Mongin, *Tetrahedron* **2016**, *72*, 2196–2205.
- [29] Q. Chen, X. Mollat du Jourdin, P. Knochel, *J. Am. Chem. Soc.* **2013**, *135*, 4958–4961.
- [30] M. Mosrin, G. Monzon, T. Bresser, P. Knochel, *Chem. Commun.* **2009**, 5615–5617.
- [31] K. Snégaroff, T. T. Nguyen, N. Marquise, Y. S. Halauko, P. J. Harford, T. Roisnel, V. E. Matulis, O. A. Ivashkevich, F. Chevallier, A. E. H. Wheatley, P. C. Gros, F. Mongin, *Chem. Eur. J.* **2011**, *17*, 13284–13297.
- [32] F. Mongin, *Chimia* **2016**, *70*, 48–52.
- [33] F. Mongin, M. Schlosser, *Tetrahedron Lett.* **1997**, *38*, 1559–1562.
- [34] F. Mongin, C. Curty, E. Marzi, F. R. Leroux, M. Schlosser, *ARKIVOC* **2015**, 48–65.
- [35] a) E. Negishi, A. O. King, N. Okukado, *J. Org. Chem.* **1977**, *42*, 1821–1823; b) E. Negishi, *Acc. Chem. Res.* **1982**, *15*, 340–348.
- [36] F. Buron, J. Y. Mérour, M. Akssira, G. Guillaumet, S. Routier, *Eur. J. Med. Chem.* **2015**, *95*, 76–95.
- [37] X. Niu, B. Yang, S. Fang, Y. Li, Z. Zhang, J. Jia, C. Ma, *Tetrahedron* **2014**, *70*, 4657–4660.
- [38] Y.-C. Teo, F.-F. Yong, S. Sim, *Tetrahedron* **2013**, *69*, 7279–7284.
- [39] J. C. Antilla, J. M. Baskin, T. E. Barder, S. L. Buchwald, *J. Org. Chem.* **2004**, *69*, 5578–5587.
- [40] M. Hedidi, W. Erb, G. Bentabed-Ababsa, F. Chevallier, L. Picot, V. Thiery, S. Bach, S. Ruchaud, T. Roisnel, V. Dorcet, F. Mongin, *Tetrahedron* **2016**, *72*, 6467–6476.
- [41] T. T. Nguyen, N. Marquise, F. Chevallier, F. Mongin, *Chem. Eur. J.* **2011**, *17*, 10405–10416.
- [42] C. R. Illig, C. L. Manthey, M. J. Wall, S. K. Meegalla, J. Chen, K. J. Wilson, S. K. Ballentine, R. L. DesJarlais, C. Schubert, C. S. Crysler, Y. Chen, C. J. Molloy, M. A. Chaikin, R. R. Donatelli, E. Yurkow, Z. Zhou, M. R. Player, B. E. Tomczuk, *J. Med. Chem.* **2011**, *54*, 7860–7883.
- [43] R. A. Hollins, M. T. L. Lima, *J. Heterocycl. Chem.* **1979**, *16*, 679–680.
- [44] D. Briel, *Pharmazie* **1991**, *46*, 455–456.
- [45] D. Horiuchi, R. Camarda, A. Y. Zhou, C. Yau, O. Momcilovic, S. Balakrishnan, A. N. Corella, H. Eyob, K. Kessenbrock, D. A. Lawson, L. A. Marsh, B. N. Anderton, J. Rohrberg, R. Kunder, A. V. Bazarov, P. Yaswen, M. T. McManus, H. S. Rugo, Z. Werb, A. Goga, *Nat. Med.* **2016**, *22*, 1321–1329.
- [46] H. E. Gottlieb, V. Kotlyar, A. Nudelman, *J. Org. Chem.* **1997**, *62*, 7512–7515.
- [47] F. Trécourt, F. Marsais, T. Güngör, G. Queguiner, *J. Chem. Soc., Perkin Trans. 1* **1990**, 2409–2415.
- [48] K. Kobayashi, T. Komatsu, K. Nakagawa, E. Hara, S. Yuba, *Heterocycles* **2013**, *87*, 2577–2587.
- [49] N. Marquise, P. J. Harford, F. Chevallier, T. Roisnel, V. Dorcet, A.-L. Gagez, S. Sablé, L. Picot, V. Thiéry, A. E. H. Wheatley, P. C. Gros, F. Mongin, *Tetrahedron* **2013**, *69*, 10123–10133.
- [50] R. A. Hollins, V. M. Salim, *Tetrahedron Lett.* **1979**, 591–592.
- [51] D. Tilly, S. S. Samanta, A.-S. Castanet, A. De, J. Mortier, *Eur. J. Org. Chem.* **2006**, 174–182.
- [52] C. F. Koelsch, *J. Am. Chem. Soc.* **1932**, *54*, 4744–4749.
- [53] N. Marquise, F. Chevallier, E. Nassar, M. Frédéricich, A. Ledoux, Y. S. Halauko, O. A. Ivashkevich, V. E. Matulis, T. Roisnel, V. Dorcet, F. Mongin, *Tetrahedron* **2016**, *72*, 825–836.
- [54] A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, *Angew. Chem. Int. Ed.* **2006**, *45*, 6040–6044.

## Key topic: Ketone functionalization



Aromatic ketones were functionalized by deprotolithiation in the presence of a zinc salt followed by iodolysis. The outcome of the reactions was analyzed in the light of the calculated  $pK_a$  values. The iodo derivatives were involved in copper-catalyzed two-fold C-N bond formation to afford fused systems based on 2-aminopyrimidines. Besides potential antibacterial effect, 2-aminobenzothiopyrano[4,3,2-*de*]quinazoline proved to inhibit PIM1 ( $IC_{50}$ :  $0.61 \mu M$ ) and CDK2/cyclin A ( $IC_{50}$ :  $2.0 \mu M$ ) kinases.

*M. Hedidi, J. Maillard, W. Erb, F. Lassagne, Y. S. Halauko,\* O. A. Ivashkevich, V. E. Matulis, T. Roisnel, V. Dorcet, M. Hamzé, Z. Fajloun,\* B. Baratte, S. Ruchaud, S. Bach,\* G. Bentabed-Ababsa\* and F. Mongin\**

**Fused systems based on 2-aminopyrimidines: synthesis combining deprotolithiation-in situ zincation with *N*-arylation reactions and biological properties**